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Abstract – Deletion of the M063 gene from myxoma virus produces a virus that is unable to replicate
in rabbit cells in vitro or in live rabbits but can be propagated in non-rabbit cell lines. A targeted M063
deletion mutant was constructed in the attenuated Uriarra strain of myxoma virus and the ability of this virus
to act as a safe, non-transmissible vaccine against myxomatosis was tested in outbred laboratory rabbits.
Immunization with the M063 deletion vaccine provided good short-term protection against lethal challenge
with virulent myxoma virus. Long-term protection was similar to reported results with heterologous live
virus, with some rabbits protected but others succumbing to challenge. Replication-deficient poxvirus
vaccines, like the Modified Vaccinia Virus Ankara (MVA) in man and the myxoma virus vaccine described
here in rabbits, are very attractive from a safety perspective. Seasonal boosting would be predicted to provide
long-term protection. Targeted host-range gene deletions could have potential for rapid development of
poxvirus vaccines in general.
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1. INTRODUCTION
Vaccination against poxvirus-induced
diseases in both man and animals has tradi-
tionally used live attenuated viruses. The best
example of this was the use of vaccinia virus
to protect against smallpox in man. Selection
of the appropriate live attenuated vaccines
for specific diseases has required a trade-off
between virulence of the vaccine virus and its
effectiveness as a vaccine. Immunization
with more virulent viruses often gives good
* Corresponding author: peter.kerr@csiro.au
long-term protection but at the cost of poten-
tial disease in some vaccinated individuals,
whereas immunization with highly attenuated
viruses may be safer but may not provide
adequate protection from challenge by the
pathogen in all cases or for prolonged periods.
This compromise is characteristic of the use
of live vaccines to protect rabbits against
myxomatosis caused by infection with the
poxvirus myxoma virus.
Myxoma virus is the type species of the
Leporipoxvirus genus. Closely related, but
with different host-adapted characteristics,
strains of myxoma virus have evolved in
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two American lagomorph species: Sylvilagus
brasiliensis in South America and Sylvilagus
bachmani in western North America. Shope
fibroma virus is another Leporipoxvirus
closely related to myxoma virus and is found
in Sylvilagus floridanus in eastern North
America. Both types of myxoma virus and
Shope fibroma virus cause localized cutaneous
fibromas in their native Sylvilagus hosts and
are spread passively on the mouthparts of
biting arthropods such as mosquitoes and
fleas [10].
In contrast to the relatively benign infec-
tions of Sylvilagus rabbits, European rabbits
(Oryctolagus cuniculus) infected with myx-
oma virus develop a lethal systemic disease
called myxomatosis [28]. Virulent South
American strains of myxoma virus were intro-
duced into Australia in 1950 as a biological
control agent for wild European rabbits and
into Europe in 1952 [11]. Vaccines to protect
domestic farmed, laboratory or pet European
rabbits from myxomatosis use either the
heterologous Shope fibroma virus, which does
not cause generalized disease in European rab-
bits [9], or tissue culture passage-attenuated
live myxoma virus strains [13, 20, 27]. Both
of these vaccines have limitations, Shope
fibroma virus induces relatively short-term
protection against myxomatosis [9,14,18] and
the attenuated SG33 strain of myxoma virus
has been associated with immunosuppression
in young rabbits [7]. Attenuated live virus
vaccines have also been investigated to protect
wild rabbits in Europe [2, 27, 30].
In Australia, live virus vaccines for the
protection of domestic and farmed rabbits
against myxomatosis have not been used for
fear that these could become established in
the wild rabbit population and reduce the
effectiveness of myxomatosis as a biological
control. A vaccine against myxomatosis
that could immunize rabbits but could not
disseminate within the immunized rabbit or
spread from rabbit to rabbit would have
potential to be used safely both in Australia
and other countries.
The myxoma virus early gene M063 is
a host-range gene essential for productive
replication of the virus in primary rabbit cells
and in all rabbit cell lines tested in vitro [3].
Targeted deletion of this gene by insertional
inactivation produces a tropism-defective virus
that can be propagated in non-rabbit cells
lines but cannot complete its replication in
rabbit cells in vitro or infected rabbits in
vivo. The M063 deletion virus enters rabbit
cells and expresses early viral genes but the
infection aborts prior to the expression of late
genes [3]. Protection following challenge with
virulent myxoma virus has been demonstrated
at 16 days after infection of laboratory rabbits
with an M063 knock-out virus [3]. Thus it
has the potential to be a completely safe
vaccine for rabbits since it cannot complete
its replication in this host and therefore cannot
disseminate within an immunized rabbit or be
transmitted to other rabbits.
M063 is one of a number of identified host-
range genes in poxviruses including the C7L
and K1L genes of vaccinia virus [3, 21, 24].
Host-range mutant viruses such as Modified
Vaccinia Ankara (MVA) and NYVACC,
which cannot complete their replication in
human cells, are potential candidates for safe
vaccines against smallpox [19]. In contrast to
M063 deletion mutants however, these viruses
express both early and late genes. Here we
describe the evaluation of an M063 deletion
mutant of myxoma virus, which expresses
only early genes, as a practical vaccine against
myxomatosis in European rabbits.
2. MATERIALS AND METHODS
2.1. Virus stocks and tissue culture
The Uriarra strain (Ur) of myxoma virus [22,26]
causes clinical myxomatosis in infected laboratory
rabbits but death is uncommon [12]. The standard
laboratory strain (SLS) of myxoma kills 100% of
infected laboratory rabbits with an average survival
time of < 13 days [25]. Virus stocks of Ur and
SLS were prepared in RK13 cells (rabbit kidney
cell line) from virus seed stocks originally obtained
as testis homogenates from infected rabbits [6].
Ur-TKO (triple knock-out) is a deletion mutant of
Ur with the M007, M010 and M011 open reading
frames (ORF) all insertionally inactivated [1]. This
virus does not cause clinical myxomatosis. Virus
stocks of Ur-TKO were prepared in RK13 cells.
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Titres for all virus stocks were determined by
plaque assay on Vero cell (African green monkey
kidney cell line) monolayers and expressed as
plaque forming units (pfu)/mL.
RK13, Vero and BSC-1 (African green monkey
kidney epithelial cell line) cells were maintained in
minimal essential medium (MEM; Gibco, Grand Is,
USA) supplemented with 10% new-born calf serum
(CSL, Melbourne, Australia, 2 mM L-glutamine
(Sigma, St. Louis, USA), 500 g/mL amphotericin
B (Sigma), 60 g/mL penicillin (CSL), 100 g/mL
streptomycin (Gibco).
2.2. Insertional inactivation
of the M063R ORF
Inactivation of the M063R ORF was achieved
by homologous recombination in Ur-infected
Vero cells transfected with the plasmid
pKSM063Rgptgus. This plasmid contains
349 bp homologous to the 3’ end and 376 bp
homologous to the 5’ end of M063 between which
was inserted the gpt-gus fusion gene under the con-
trol of a synthetic early/late poxvirus promoter [8].
Recombination between the Ur genome and the
plasmid results in the insertion of the gpt-gus
gene into the middle of the M063R ORF and the
deletion of 498 bp of the ORF. Recombinant virus
was selected by resistance to mycophenolic acid
(Sigma) and screening for blue plaques in the
presence of X-gluc (5-bromo-4-chloro-3-indolyl-
-D-glucuronic acid; Progen Industries, Ipswich,
Australia). Transfection of cells and selection of
recombinant viruses for resistance to mycophenolic
acid (Sigma) and expression of  glucuronidase
were as previously described [16, 17] respectively.
Isolation of single blue-staining plaques was made
in BSC-1 monolayers because plaque purification
was easier from the foci of infected cells formed
on these monolayers rather than the holes formed
on Vero cell monolayers. Following six rounds
of plaque purification, the recombinant virus
was demonstrated free of parental virus by PCR
analysis and failure to replicate in RK13 cells.
Cloning and sequencing of the M063R ORF from
this virus confirmed that the sequence was identical
to the plasmid pKSM063Rgptgus sequence. The
resulting virus was termed UrM063. Stocks of
this virus were prepared in Vero cell monolayers.
2.3. Vaccine trials
Vaccine trials were conducted in outbred
laboratory rabbits under containment level 2 (PC2)
conditions as approved by the Commonwealth
of Australia Office of the Gene Technology
Regulator. All trials were approved by the CSIRO
Sustainable Ecosystems Animal Ethics Committee.
Rabbits were housed in individual cages with free
access to water and commercial pelleted rabbit
food under a 12 h light/dark cycle. Vaccination
was by intradermal inoculation on the left thigh
with 100 000 pfu of UrM063 in 100 L of
PBS. Boosting was with the same dose of virus
inoculated on the right thigh. Boosting with
Ur-TKO used 50 pfu of virus. This dose has
been shown to provide protection from lethal
challenge [1]. Rabbits were challenged by the
inoculation of 1 000 pfu of SLS intradermally on
the left thigh. Each rabbit was physically examined
daily during the trials and rectal temperatures
measured; a temperature of ≥ 40 ◦C was regarded
as significantly elevated.
2.4. Antibody assays
ELISA and plaque reduction neutraliza-
tion assays were performed as previously
described [15]. ELISA titrations were made using
two-fold dilutions of serum from 1:100. Titres
were expressed as the reciprocal of the final
dilution producing an OD405 0.1 units above the
negative control serum. Sera with an OD < 0.1
above the negative control at a dilution of 1:100
were recorded as a titre of 0. Plaque reduction
neutralization assays used two-fold dilutions from
1:10 of heat-inactivated serum (10 min, 56 ◦C)
and constant virus concentration (∼100 pfu per
well). Titres were expressed as the reciprocal of
the lowest dilution giving a ≥ 50% reduction in
the number of plaques compared to control normal
serum. Sera that did not cause at least 50% plaque
reduction at 1:10 dilution were assigned a titre of 0.
For both assays, a four-fold change in titre in an
individual rabbit was regarded as significant.
2.5. Immunofluorescence staining
RK13 or Vero cell monolayers infected with Ur
or UrM063, at a multiplicity of infection (MOI)
of one, for 24 h or uninfected control monolayers,
were fixed with 1:1 (v/v) methanol:acetone (Sigma)
for 10 min, washed with PBS pH 7.2 and stored
at –20 ◦C until used. The monolayers were probed
with monoclonal antibody 3B6E4 [5] and binding
detected with FITC-conjugated goat anti-mouse
IgG (BioRad, Richmond, USA). Fluorescence was
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Figure 1. Replication of the Ur strain of myxoma
virus and UrM063 in Vero or RK13 cells. RK13
or Vero cell monolayers were infected with Ur or
UrM063 at MOI 0.1 pfu. Duplicate monolayers
were harvested at 0, 12, 24, 36, 48, 72 and 96 h after
infection. Virus titres were determined by plaque
assay on Vero cell monolayers; mean titres for
duplicate monolayers are shown.
visualized using a Leitz Fluovert FS microscope
and recorded with a Spot RT digital camera
(Diagnostic instruments, Australia).
3. RESULTS
3.1. Replication of Ur and UrM063 in Vero
or RK13 cells
Both the parental Ur and UrM063 had
similar replication kinetics in Vero cells at
MOI of 0.1. However, UrM063 was unable
to replicate in the rabbit cell line RK13
(Fig. 1). Similar results were obtained with
MOI of three (data not shown). Late gene
expression of myxoma virus was examined
in RK13 and Vero cell monolayers infected
with Ur or UrM063. Cell monolayers were
probed with monoclonal antibody 3B6E4 [5]
which binds to a 42 kDa myxoma virus
core protein which is not expressed if DNA
replication is inhibited with AraC (cytosine
1--D-arabinofuranoside). This protein is
conserved in South American and North
American myxoma viruses and Shope fibroma
virus (data not shown). Figure 2 demonstrates
that late gene expression was occurring in Vero
cells infected with both Ur and UrM063
(panels C and E). However, in RK13 cells
there was a clear difference between Ur and
UrM063 infected cells with almost all cells
infected with Ur showing strong fluorescence
while those cells infected with UrM063
stained poorly for the viral late antigen
although some cells show weak fluorescence
which may be due to a small amount of
protein expression or to the input virus
(panels D and F).
3.2. Vaccination trials
3.2.1. Trial 1: vaccination with UrM063
and SLS challenge
Six adult male rabbits were vaccinated
with UrM063. The only clinical response
to immunization was a pink lump at the
inoculation site from day 5. Initially 0.3–
0.5 cm in diameter, this swelling increased to
as much as 1.5 cm in diameter and resolved
completely by day 21. Rectal temperatures
remained within normal limits during this
time. Six weeks after vaccination, all six
rabbits were challenged with a lethal dose of
the virulent myxoma virus SLS. The clinical
signs in response to challenge are summarised
in Table I. All of the rabbits survived the
SLS challenge. The key features were the
rapid development of a cutaneous response
at the inoculation site within 24 h which was
quickly resolved and the presence of small,
rapidly-resolved, cutaneous or mucocutaneous
secondary lesions. For comparison with the
clinical signs of unvaccinated control rabbits
challenged with SLS, see Table II.
3.2.2. Trial 2: vaccination with UrM063 plus
boosting and SLS challenge
Six 12-week-old male rabbits were vacci-
nated with UrM063. There was no difference
in the response to vaccination compared with
the previous trial despite the younger age of
the rabbits. These rabbits were boosted with
UrM063 four weeks later. A 0.5–1.2 cm pink
lump developed at the boost site within 24 h
that increased to 0.8–1.5 cm by 3 days after
boosting and had regressed by 9 days after
boosting. Rectal temperatures remained in the
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Figure 2. Immunofluorescent detection of myxoma virus antigen in infected cells. Vero cell monolayers
were mock infected (A), infected with Ur (C) or UrM063 (E) at a MOI of 1. RK13 cell monolayers
were mock infected (B), infected with Uriarra (D) or UrM063 (F) at a MOI of 1. After 24 h, cells were
fixed and probed with the monoclonal antibody 3B6E4, specific for a late myxoma virus antigen. Original
magnification 40×.
normal range during this time. Six weeks after
boosting the rabbits were challenged with SLS
myxoma virus. Within 24 h, all rabbits devel-
oped a raised red lump around 1 cm in diame-
ter at the challenge inoculation site. By 3 days
after challenge, these lesions were 1.5–3 cm
in diameter and had a black centre. Secondary
lesions only occurred on 2 of the 6 rabbits,
at the ear margins and on the face; no more
than 5 small secondary lesions were visible on
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Table I. Clinical signs in UrM063 vaccinated rabbits challenged with SLS.
Day post-inoculation Clinical signs
1 0.8–1.2 cm diameter pink lesion at inoculation site
2 All rabbits have rectal temperatures ≥ 40 ◦C
3 1.5–2.5 cm red/crimson protuberant lesion at inoculation site.
5/6 rabbits have normal temperatures
5 Lesions at inoculation site are black 2–4 cm in diameter. Secondary lesions on
5/6 rabbits on eyelids, ears, face and body. All animals had rectal
temperature ≥ 40 ◦C
7 Lesions at inoculation site scabbed over. Secondary lesions had all turned black and
were 0.5–1 cm in diameter on eyelids, ears, anus, scrotum, face, nostrils and body.
4/6 animals had a rectal temperature ≥ 40 ◦C
8 2/6 rabbits had snuffly breathing with slight mucopurulent discharge from nostrils
and mild anogenital swelling. 3/6 rabbits had temperatures ≥ 40 ◦C
9 2/6 animals had recovered except for hard black scabs over inoculation site and over
mild the secondary lesions; 3 rabbits had snuffly breathing and nasal discharge,
anogenital swelling and temperatures ≥ 40 ◦C. All secondary lesions were black
and regressing
13 Lesions at inoculation sites covered in hard black concave scabs.
1 rabbit still had slight nasal discharge and snuffly breathing but rapidly recovering.
Anogenital swelling had regressed.
Some weight loss in 2 of the rabbits that had been worst affected.
All rabbits had temperatures < 40 ◦C
21 All animals recovered although some have lumpy misshapen ear margins and
small black scabs on face and body
any rabbit. By 6 days after challenge, the pri-
mary lesions were covered with a black scab
although some primary lesions had small sec-
ondary lesions around the periphery. By 9 days
after challenge, the rabbits were completely
recovered apart from scabs on the primary
and secondary lesions. Only 2 of the rabbits
had rectal temperatures ≥ 40 ◦C following
challenge and all temperatures were within
the normal range from day 6 after challenge.
Table II. Clinical signs in unvaccinated control rabbits challenged with SLS.
Day post-inoculation Clinical signs
3 0.5 cm swelling at inoculation site in 1/3 rabbits
4 2/3 rabbits have rectal temperatures ≥ 40 ◦C; 1/3 has 1 cm swelling at inoculation site;
2/3 have slight skin thickening at inoculation site and one has slightly swollen eyelid
margins and nose
5 1–2 cm swelling at inoculation site; red eyelid margins
7 Red swollen eyelids with slight serous to mucoid discharge, slightly swollen nose
and ears; mild to moderate anogenital swelling
8 Primary lesion 1.5–2.5 cm diameter; swollen eyelids – eyes half closed by swelling in
one rabbit – mucopurulent conjunctival discharge, snuffling respiration and moderate
to severe anogenital swelling in all 3 rabbits. Rabbits moderately to severely ill
10 One rabbit dead and one euthanized. Very swollen drooping ears, eyes completely
closed by eyelid swelling, mucopurulent discharge from conjunctivae and nose,
straining to breathe with head and neck extended, severely swollen anogenital
region in 2/3 rabbits and severely swollen scrotums in all three rabbits. Rectal
temperature of euthanized rabbit 37.5 ◦C
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3.2.3. Trial 3: vaccination with UrM063 plus
boost with live attenuated virus
Six 12-week-old male rabbits were vacci-
nated with UrM063 and 4 weeks after immu-
nization the rabbits were boosted with 50 pfu
of Ur-TKO. A small lesion developed at the
boost site 3 to 4 days after boosting which,
by 6 days, ranged from 0.5–1.5 cm in diame-
ter except on one rabbit which had a 2 × 3 cm
lesion. These lesions scabbed and regressed
over the next 5–10 days. No secondary lesions
were visible and rectal temperatures remained
within the normal range. Six weeks after
boosting the rabbits were challenged with SLS
myxoma virus. Three of the challenged rabbits
had a very limited response to challenge that
was characterized by a pink lesion at the chal-
lenge site within 24 h which had started to scab
by 4 days after challenge. Only one of these
rabbits developed a few, very small, secondary
lesions on the ears and eyelids. The other 3
rabbits exhibited numerous small secondary
lesions on the eyelids, anus, nose, face or
ears, slightly obstructed nasal passages, mild
ano-genital swelling, fever ≥ 40 ◦C and some
weight loss. However, at no point were these
rabbits seriously debilitated.
3.2.4. Trial 4: vaccination with UrM063 plus
boosting and long-term challenge
To determine the duration of protection, 12
male rabbits approximately four months old
were vaccinated with UrM063 and boosted
with the same virus 4 weeks later. Thirty-
five weeks after the initial vaccination, the
rabbits were challenged with SLS myxoma
virus. As controls, 3 unvaccinated rabbits were
challenged with SLS at the same time. Clinical
signs in these control rabbits are described
in Table II and the rectal temperatures are
shown in Figure 3A. One control rabbit had
a 0.5 cm primary lesion at the challenge site
by day 3 after challenge and 2 rabbits had
rectal temperatures ≥ 40 ◦C. It was not until
day 5 that all 3 control rabbits had distinct
primary lesions at the challenge site. The
control rabbits developed typical generalized
severe myxomatosis and either died or were
euthanized between days 10 and 13 after
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Figure 3. Rectal temperatures of rabbits challenged
with SLS myxoma virus 35 weeks after vaccination
with UrM063 or unvaccinated controls. (A) Un-
vaccinated control rabbits. (B) Five rabbits which
were resistant to challenge. (C) Seven rabbits which
developed generalized myxomatosis following
challenge. A temperature of ≥ 40 ◦C (indicated by
dashed line) was regarded as significantly elevated.
infection. In contrast to the control rabbits,
the vaccinated rabbits exhibited an accelerated
tissue response to challenge (Tab. III). By
day 2, all 12 rabbits had an 0.5–2.5 cm
swelling at the challenge site and by day 3,
11/12 rabbits had rectal temperatures ≥ 40 ◦C
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Table III. Clinical signs in long-term challenged rabbits.
Day post-challenge Clinical signs
1 4/12 rabbits had a detectable response at the challenge site ranging from slight skin
thickening to a 1 cm diameter swelling
2 All rabbits had 0.5–2 cm diameter swellings at challenge site
3 11/12 rabbits had rectal temperatures ≥ 40 ◦C. 3/12 rabbits had primary lesions that
were black in the centre. 3 rabbits had thickened ears
4 11/12 rabbits had rectal temperatures ≥ 40 ◦C. Primary lesions ranged from
1–6 cm diameter
5 8/12 rabbits had rectal temperatures ≥ 40 ◦C. Some secondary signs of myxomatosis
such as anogenital redness and ears and eyelids slightly thickened
6 11/12 rabbits had rectal temperatures ≥ 40 ◦C. 5/12 primary lesions now black in centre.
Some discrete secondary lesions are already black. Some rabbits have swollen noses,
eyelids, base of ears and red slightly swollen anogenital areas. One rabbit had very
rapid respiration and depressed demeanour
7 10/12 rabbits had rectal temperatures ≥ 40 ◦C. Most primary lesions black in centre
and some are scabbing. Clinical signs ranged from severe anogenital swelling,
swollen ears and eyelids to just a primary lesion
8 9/12 rabbits had rectal temperatures ≥ 40 ◦C. Clinical signs ranged from localized
primary lesion to severe generalized myxomatosis. Clinically affected rabbits had mild
to severe anogenital swelling and swollen scrotums, some conjunctival mucopurulent
discharge, swollen, drooping ears, discrete secondary lesions on face and eyelids
9 5/12 rabbits were rapidly recovering and had normal temperatures; 5/12 rabbits had
rectal temperatures ≥ 40 ◦C and clinical signs of myxomatosis continued to develop
with snuffling, laboured respiration due to congestion of nasal passages, mucopurulent
conjunctival discharge, eyelids swollen and half closed, swollen anogenital regions and
scrotums and swollen drooping ears
10 5/12 rabbits were essentially completely recovered. One rabbit was found dead and
one had a subnormal temperature (37.4 ◦C) and was euthanized. The other 5 rabbits had
temperatures ≥ 40 ◦C with clinical signs ranging from moderate to severe generalized
myxomatosis. One of these rabbits was starting to recover
15 All temperatures were < 40 ◦C. 3/5 of the severely ill rabbits were clearly recovering
although 4/5 were still quite ill. Clinical signs ranged from moderate to severe
generalized myxomatosis.
(Figs. 3B and 3C). Five of the vaccinated
rabbits developed very mild clinical signs of
myxomatosis characterized by a 1.5–2.5 cm
diameter primary lesion at the challenge
site, slightly swollen ears, eyelids and face
with scattered small secondary lesions. These
rabbits had essentially recovered by day 9
and rectal temperatures had returned to normal
(Fig. 3B). The other seven vaccinated rabbits
developed moderate to severe myxomatosis
with prolonged fever (Fig. 3C). At day 10,
one vaccinated rabbit was dead, one was
euthanized, because of severe illness and
a subnormal rectal temperature, and the
remaining five were moderately ill. These five
rabbits became more seriously ill over the
next 2 to 3 days with severely congested
nasal passages causing respiratory distress.
However, by day 15, 4 of the 5 were recovering
and based on experience with similar clinical
cases would most likely have survived. The
fifth was still very ill but starting to recover.
All five rabbits were euthanized at day 15 on
humanitarian grounds.
3.3. Serum antibody titres following
immunization
In the six weeks following immunization
with UrM063, serum antibodies to myxoma
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virus were barely detectable with ELISA
titres ranging from 0 to 200 (Fig. 4A).
Neutralizing antibodies were undetectable
(Tab. IV A). Seven days after challenge with
SLS myxoma virus, ELISA titres increased
to 6 400–12 800, while at 2 weeks after
challenge, neutralization titres ranged from
640 to > 20 480.
Rabbits immunized with UrM063 and
then boosted with the same virus had a
significant rise in ELISA titre in the week
following the boost. This titre increased again
following challenge (Fig. 4B). None of the
rabbits had detectable neutralizing antibody
prior to boosting. However, 5 of 6 rabbits
developed neutralizing antibody titres ranging
from 10 to 160 two weeks after boosting
(Tab. IV B). On the day of challenge, six
weeks after boosting, all six rabbits had
neutralizing antibody titres ranging from 10–
80. Two weeks after challenge these titres were
320 to 10 240.
When rabbits were boosted with Ur-TKO,
3 of 6 rabbits had a significant rise in ELISA
titre with titres at two weeks after boosting of
1 600, 1 600 and 400 (Fig. 4C). These three
rabbits also developed neutralizing antibody
titres of 40 to 640 (Tab. IV C). The other three
rabbits had no increase in antibody titre and
antibody could not be detected on the day
of challenge. All six rabbits had substantial
rises in antibody titres following challenge.
ELISA titres ranged from 3 200 to 102 400
and neutralizing titres from 640 to > 20 480.
Two of the three rabbits that failed to develop
neutralizing antibody titres had mild to
moderate clinical signs of disease following
challenge with development of numerous
small secondary lesions and slight occulo-
nasal discharge. However, one of the animals
with neutralizing antibody titres developed
similar clinical signs while the third rabbit
that failed to develop neutralizing antibody
had only a few secondary lesions (Tab. IV C).
In the long-term studies, only virus neu-
tralization titres were measured because these
have the potential to control virus infection.
0 1 2 3 4 5 6 7 8 9 10 11 12
100
400
1600
6400
25600
102400
0 1 2 3 4 5 6 7 8 9 10 11 12
100
400
1600
6400
25600
102400
0 1 2 3 4 5 6 7 8 9 10 11 12
100
400
1600
6400
25600
102400
Time (weeks) after immunization
ertit
 yd
obit
n
a
 
m
ur
eS
A
B
C
Figure 4. Serum antibody titres to myxoma virus
measured by ELISA. (A) Rabbits vaccinated with
UrM063 and challenged at 6 weeks (arrow)
with SLS. (B) Rabbits vaccinated with UrM063,
boosted at 4 weeks with UrM063 (arrow)
and challenged at 10 weeks (arrow) with SLS.
(C) Rabbits vaccinated with UrM063, boosted at
4 weeks (arrow) with Ur-TKO and challenged
at 10 weeks (arrow) with SLS.
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Table IV. Serum neutralizing antibody titres in immunized rabbits.
A. Rabbits vaccinated with UrM063
Rabbit Titre at challenge Titre post challenge
184 < 10 > 20 480
179 < 10 2 560
183 < 10 > 20 480
176 < 10 640
187 < 10 5 120
154 < 10 5 120
B. Rabbits vaccinated with UrM063 and boosted with UrM063
Rabbit Titre at Titre at Titre at challenge Titre at Clinical signs at
boost 6 weeks (10 weeks) 12 weeks challenge
(4 weeks)
281 < 10 40 20 2 560 Primary only
278 < 10 160 80 10 240 Primary only
282 < 10 < 10 10 5 120 Few secondaries
284 < 10 80 10 320 Primary only
288 < 10 10 10 5 120 Few secondaries
287 < 10 40 20 1 280 Primary only
C. Rabbits vaccinated with UrM063 and boosted with attenuated live virus
Rabbit Titre at Titre at Titre at challenge Titre at Clinical signs at
boost 6 weeks (10 weeks) 12 weeks challenge
(4 weeks)
285 < 10 < 10 < 10 10 240 Mild-moderate
291 < 10 160 80 640 Primary only
289 < 10 40 10 > 20 480 Mild-moderate
290 < 10 640 320 1 280 Primary only
275 < 10 < 10 < 10 5 120 Few secondaries
293 < 10 < 10 < 10 > 20 480 Mild moderate
D. Long term trials for rabbits vaccinated with UrM063 and boosted with UrM063
Rabbit Titre post- Titre at Titre 15 days Clinical signs at challenge
No. boost challenge post-challenge
403 10 < 10 > 640 mild
401 20 < 10 > 640 mild
379 40 20 > 640 mild
405 10 < 10 80 Mild-moderate
395 160 < 10 640 Mild to moderate
387 80 < 10 > 640 Generalized
385 80 < 10 > 640 Generalized
386 40 < 10 640 Generalized
390 80 < 10 640 Severe
391 10 < 10 > 640 Severe
392 80 < 10 Not tested Fatal
400 80 < 10 Not tested Fatal
All 12 rabbits had neutralizing antibody
detectable at 7 days after boosting with titres
ranging from 10–160 (Tab. IV D). However,
on the day of challenge, 31 weeks later,
only one rabbit had neutralizing antibody
detectable at a titre of 20. Following challenge,
neutralization titres ranged from 80 to 640
for the 10 rabbits surviving at day 15. Blood
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samples were not available for the two rab-
bits that died prior to day 15. Inspection of
Table IV D indicates that there was no direct
correlation between the titre of neutralizing
antibody after boosting and the severity of
clinical disease following challenge.
4. DISCUSSION
Vaccination with UrM063 provided good
short-term protection from lethal challenge
with a dose of virus much greater than would
normally be delivered by a flea or mosquito
vector. Immunization was extremely safe with
the only side-effect being a moderate swelling
at the inoculation site from day five which
resolved completely within three weeks of
vaccination. This was probably due to a
cell-mediated immune response to antigen
produced by early gene expression in dermal
cells since the virus cannot replicate in rabbit
cells to induce the classic ‘myxoma’ at the
inoculation site.
Rabbits immunized with UrM063 did
not develop high titres of serum antibody to
myxoma virus, measured by either ELISA
or neutralization, prior to boosting. In both
assays, viral proteins of the intracellular
mature virus (IMV) are the predominant
antigens and it is unlikely that key structural
proteins that make up the outer layers of
either IMV or extracellular enveloped virus
(EEV) would be expressed by rabbit cells
infected with UrM063 as these proteins are
encoded by late genes. However, vaccination
with this replication-defective virus appeared
to prime both B and T cells, which responded
rapidly to boosting with UrM063 and to
challenge with virulent SLS myxoma virus.
The T cell response was demonstrated by
the rapid tissue response at the site of
challenge or boosting and B cell priming by
anamnestic serum antibody responses to IMV
following challenge or boost. At six weeks
after vaccination this provided good protection
from lethal challenge with virulent myxoma
virus. It seems likely that B and T cells are
being primed by IMV structural proteins in the
immunizing virus and stimulated to proliferate
and, in the case of B cells, differentiate into
plasma cells, by the same proteins in the
boosting dose of virus or in the replicating
challenge virus. Comparison of Figures 4A
and 4B support this model as there is a
much greater response to the live virus than
to the boost with UrM063. Any significant
late protein synthesis or UrM063 viral
replication is ruled out by the lack of antibody
to IMV following the primary immunization.
Boosting with a very low dose of live
attenuated virus (Ur-TKO) did not show any
advantages over boosting with UrM063 and
may have been less effective as only three of
six rabbits had a rise in antibody titre. This
was possibly because the immunized rabbits
controlled replication of this very attenuated
virus. Higher doses of Ur-TKO may have been
more effective as a boost but when used as a
primary immunization there is no difference
in protection between 50 and 5 000 pfu of
Ur-TKO [1].
From the shorter term studies, it can be
concluded that immunized and boosted rabbits
have good protection from high dose lethal
challenge for at least 10 weeks. However,
challenge studies at 35 weeks after primary
immunization showed that only 5/12 of
rabbits retained good protection. Only one
of the rabbits had detectable neutralizing
antibody at this time which contrasts with
rabbits recovered from natural infection which
have neutralizing antibodies detectable for
> 12 months and are strongly protected
from disease on challenge [15]. All of the
immunized rabbits in the long-term trial
developed a rapid response at the challenge
site within 48 h. That this was initially largely
due to an immune response rather than virus
replication is seen by comparison with the
control rabbits which did not develop a
primary lesion at the challenge site until
day three or four. Similarly 11/12 challenged
rabbits developed a fever of ≥ 40 ◦C within
three days of challenge compared with 2
of 3 control rabbits at 4 days. There was
no apparent correlation between the initial
response to challenge and the subsequent
course of the disease. Since the rabbits had
very low or undetectable levels of neutralizing
antibody at challenge, it seems likely that
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a T cell memory response is critical to
controlling initial virus replication and spread
while antibody is important to limit later viral
spread and to clear the virus. It is possible that
the rabbits that controlled the disease had a
qualitatively or quantitatively different T cell
response to the severely affected rabbits.
The degree and duration of protection
provided by immunization with UrM063
compared well with that provided by immu-
nization reported with the heterologous Shope
fibroma virus [9, 14]. For example, 13/20 rab-
bits vaccinated with Shope fibroma virus died
following challenge with virulent myxoma
virus seven weeks after immunization [18].
Immunization with an attenuated homologous
live myxoma virus SG33 provides protection
that lasts for a more prolonged period in most,
but not all, immunized rabbits. In a set of
6 trials [27], 2 of 59 rabbits died following
challenge 21 days after vaccination; protection
waned between 6 and 8 months after vaccina-
tion and was regarded as unsatisfactory by 8
months. Vaccination with SG33 followed by
a boost at 8 weeks gave reasonable protection
at 8 months but by 12 months 50% of ani-
mals exhibited some degree of myxomatosis
following challenge [27]. In another set of
trials, rabbits vaccinated with SG33 at 4 or 6
weeks of age were regarded as insufficiently
protected from challenge after approximately
10 weeks [23]. This vaccine has also been
demonstrated to induce immunosuppression in
vaccinated rabbits [7, 18]. Compared to these
vaccines UrM063 is extremely safe, and
there is no possibility of it transmitting to other
rabbits. Thus it would be acceptable for use in
Australia as it produces no risk to the use of
myxomatosis as a biological control. It could
be used strategically to provide protection
from myxomatosis during the peak incidence
of the disease by immunizing domestic rabbits
in the spring followed by a boost. Further trials
would be needed to optimize the vaccine dose
and boosting regime. In addition, UrM063
could be further genetically engineered to
express the Rabbit Haemorrhagic Disease
Virus capsid gene under the control of an early
promoter by replacing the gptgus fusion gene
and thus potentially provide protection against
the two major viral diseases of rabbits as has
been previously described for a recombinant
myxoma virus [2, 4, 29].
The research described demonstrates that
deletion of host-range genes could be used to
provide safe poxvirus vaccines, for diseases
of livestock or humans, that could not trans-
mit and thus potentially endanger immunoin-
competent contacts and that such vaccines can
protect even if only early genes are expressed.
However, while very attractive from a safety
perspective, the long-term trials indicate that
such vaccines may require care with boosting
for ongoing protection.
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